Lipids-based products developer Enzymotec files for a $75 million IPO

By
A A A

Enzymotec, which develops lipid-based nutritional ingredients and medical foods, filed on Thursday with the SEC to raise up to $75 million in an initial public offering. The Migdal Ha'Emeq, Israel-based company, which was founded in 1998 and booked $51 million in sales for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol ENZY. Enzymotec initially filed confidentially on July 10, 2013. BofA Merrill Lynch and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ENZY

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

57,375,820
  • $16.20 ▼ 0.80%
46,357,695
  • $102.13 ▲ 1.23%
39,856,106
  • $3.59 ▲ 0.84%
36,749,915
  • $19.21 ▲ 5.38%
35,094,671
  • $74.63 ▼ 1.75%
25,538,058
  • $48.06 ▼ 0.23%
24,241,250
  • $38.18 ▲ 1.03%
22,422,839
  • $11.20 ▲ 3.70%
As of 8/27/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com